H.C. Wainwright views the the initial Phase 1 for ZW191 results as “highly encouraging.” It reiterates a Buy rating on Zymeworks (ZYME) with a $26 price target ZW191 demonstrated an objective response rate of 44% for all response-evaluable participants across all dose levels, the analyst tells investors in a research note. H.C. Wainwright believes ZW191’s initial signals are “quite encouraging” compared with Elahere, which is FDA-approved only for FRa-high ovarian cancer patients.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks assumed with an Equal Weigh at Wells Fargo
- Promising Early-Stage Data and Strategic Initiatives Drive Buy Rating for Zymeworks’ ZW191 Program
- Buy Rating for Zymeworks’ ZW191 Driven by Promising Efficacy and Favorable Safety Profile
- Zymeworks Reports Promising Phase 1 Results for ZW191 in Cancer Treatment
- Zymeworks reports preliminary results from Phase 1 study of ZW191